Evaluation of the F&P Mask, US, 2026

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22+
SponsorFisher and Paykel Healthcare

About this trial

This clinical investigation is designed to validate and confirm the overall performance, safety, usability, reliability, and acceptability of the F\&P Licorice mask in a home environment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Are ≥22 years of age

Weigh ≥66 pounds

Have been prescribed PAP/NIV therapy by a physician

Are an existing PAP/NIV therapy mask user with ≥3 months of use prior to enrolment in the clinical investigation*

Disqualifiers

Are intolerant to PAP/NIV therapy

Possess, or suffer from, anatomical or physiological conditions which make PAP/NIV therapy inappropriate

Are required to use PAP/NIV therapy for >12 hours per day or for extensive periods, not including sleep or naps

Are trying to get pregnant, are pregnant, or think they may be pregnant

Trial design

Design model

Single group

Treatments tested in this trial

  • F&P Licorice Mask

    Device

    PAP/NIV Therapy Mask

Treatment groups

45 Participants
are divided into 1 treatment group
Group A: InterventionOther 1 intervention

Trial outcomes

Primary outcomes

1

Therapeutic Efficacy

Determined by Apnea-Hypopnea Index (AHI) recorded on PAP therapy machines after 14 days of use. The Apnea-Hypopnea index (AHI) is the sum of the apneas and hypopneas divided by the hours of sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and \>= 30/h = severe AHI is measured by dividing the total number of recorded apneas (complete breathing stops) and hypopneas (shallow breathing episodes) by the total number of hours a person slept during an overnight sleep study or using a PAP device. Higher AHI values represent worse outcomes. There is no maximum theoretical index score.

Time frame
Baseline and 14±5 days
2

Epworth Sleepiness Scale

All relevant time points used in the calculation in the Time Frame (e.g., baseline and 14±5 days). Note: change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 14±5 days minus value at baseline). Change between two time points is reported. Scale range: 0 (minimum score) to 24 (maximum score) (higher scores represent worse outcomes)

Time frame
14±5 days
3

Patient and Clinical Global Impression (PGI/CGI)

Determined by Patient Global Impression (PGI) and Clinical Global Impression (CGI) assessments completed at baseline and Day 14. Baseline symptom severity is assessed using a 6-point scale (1 = No symptoms to 6 = Very severe symptoms). Change from baseline is assessed using a 7-point scale (1 = Very much better to 7 = Very much worse; 4 = No change). Higher severity scores indicate worse symptoms. For change assessments, lower scores indicate improvement and higher scores indicate worsening. PGI is completed by the patient and CGI is completed by the investigator/clinician.

Time frame
Baseline and 14±5 days

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.